Dr. Kristin K. Ancell, MD

Dr. Ancell practices at Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center.

Dr. Ancell's NPI, 1437206232, was assigned on January 4, 2007. Dr. Ancell graduated from University of Missouri School of Medicine in 2005. Dr. Ancell holds Tennessee license 289901.

Dr. Ancell's primary practice is Vanderbilt University Medical Center, at 1211 Medical Center Drive, Nashville, TN 37232 in Davidson County. The practice phone is (615) 322-3454.

Dr. Ancell's primary practice is Vanderbilt University Medical Center in Nashville, Tennessee, part of Vanderbilt University Medical Center. Dr. Ancell is also affiliated with Vanderbilt Wilson County Hospital. The medical group on file is Vanderbilt University Medical Center. Dmand AI also links Dr. Ancell to 1 more group practice or clinic, named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Ancell practices, 3 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Ancell's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dr. Ancell is board certified in medical oncology by the American Board of Internal Medicine. Dmand AI has Dr. Ancell's licenses on file in 2 states: Tennessee and Alabama.

Dmand AI lists breast cancer, chronic leukemia, lung cancer, multiple myeloma and prostate cancer among the conditions Dr. Ancell treats.

CMS data shows 666 Medicare services from Dr. Ancell across 6 procedure codes in 2024, for 245 Medicare patients. Medicare paid $40,444 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 245 Medicare patients who saw Dr. Ancell in 2024. The largest group is 65 to 74, with 114 patients. 75% of them have high blood pressure, and 73% have high cholesterol. 6% are also on Medicaid. Their average risk score is 2.60, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Ancell's median patient age at 72, with 36% women.

In 2024, Dr. Ancell wrote 900 Medicare Part D claims for 103 patients. 72% of them were for generic drugs. CMS names the drug for 737 of them, across 28 drugs with 11 or more claims each, at $1,338,635 in total drug cost. In 2023, CMS named 540 claims across 20 drugs.

Dr. Ancell accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Ancell as offering telehealth.

Dmand AI links 13 papers to Dr. Ancell, published from 2015 to 2022. 2019 was the busiest year, with 2. The most frequent topics are Melanoma, Antibodies, Monoclonal, Humanized and Antineoplastic Agents, Immunological. Dr. Ancell's most frequent co-authors are Anthony Brent Daniels, MD, Jeffrey A. Sosman, MD and Landon Carter Brown, MD.

Dmand AI links Dr. Ancell to 4 clinical trials, 2 of them phase 2 studies. 3 are still active or recruiting. Conditions studied include Uveal Melanoma, Uveal Neoplasms and Melanoma. National Cancer Institute (NCI) sponsors the most, 3.

CMS Open Payments shows 4 general payments to Dr. Ancell from 3 drug and device companies from 2024 to 2025. Food and beverage make up the largest share, 87% of the total. Novartis Pharmaceuticals Corporation paid the most, $58.

Dr. Ancell graduated from University of Missouri School of Medicine in 2005. Dr. Ancell is a member of ASCO.

Dr. Ancell is in network with 12 carriers, including Cigna, Blue Cross Blue Shield of Michigan and Aetna. PPO plans come from the most carriers, 7. Check the plan with the practice before a visit.